HT treatment with estrogens alone or in combination with progestogens was associated with a small to moderate improvement in sexual function , particularly in pain , when used in women with menopausal symptoms or in early postmenopause ( within five years of amenorrhoea ) , but not in unselected postmenopausal women .
The current evidence does not suggest an important effect of tibolone or of SERMs alone or combined with estrogens on sexual function .
BACKGROUND The perimenopausal and postmenopausal periods are associated with many symptoms , including sexual complaints .
OBJECTIVES To assess the effect of hormone therapy ( HT ) on  sexual function in perimenopausal and postmenopausal women .
Body mass index does not influence response to treatment, nor does body weight change with lower doses of conjugated estrogens and medroxyprogesterone acetate in early postmenopausal women
Objective : To determine the effects of lower doses of conjugated estrogens ( CE ) alone or in combination with medroxyprogesterone acetate ( MPA ) on body weight and to evaluate the influence of body mass index ( BMI ) on the effect of lower-dose CE or CE/MPA on vasomotor symptoms , vaginal atrophy , bone mineral density ( BMD ) , endometrial safety , and side effects such as endometrial bleeding and breast pain . Design : In this large clinical trial [ the Women 's Health , Osteoporosis , Progestin , Estrogen ( Women 's HOPE ) study ] , 2,673 healthy , postmenopausal women with intact uteri were r and omized for 1 year of CE 0.625 , CE 0.625/MPA 2.5 , CE 0.45 , CE 0.45/MPA 2.5 , CE 0.45/MPA 1.5 , CE 0.3 , CE 0.3/MPA 1.5 ( all doses mg/d ) , or placebo .  Weight , BMI , number and severity of hot flushes , vaginal atrophy ( as determined by the vaginal maturation index ) , bleeding profiles , breast pain , and endometrial biopsies were evaluated . A subset of 822 women was r and omized into a 2-year sub study to evaluate changes in BMD with lower-dose CE or CE/MPA regimens . Results : After 1 year of treatment , a small but significant ( P < 0.05 ) gain in body weight from baseline was observed in all arms of the study , the largest increase in body weight occurring in the placebo group [ 1.15 ± 0.21 ( SE ) kg ] . Body mass index had no significant effect on changes from baseline for vasomotor symptoms , bleeding patterns , vaginal atrophy , BMD , endometrial safety , or breast pain when analyzed both by analysis of covariance with baseline BMI as covariate or when participants were grouped into BMI less than 25 kg/m2 and BMI of 25 kg/m2 or greater . In placebo-treated women , vaginal atrophy was significantly greater ( P < 0.05 ) in women with a BMI less than 25 kg/m2 compared with a BMI of 25 kg/m2 or greater . Conclusions : Lower- and st and ard-dose regimens of CE or CE/MPA are not associated with greater weight gain  than placebo . In addition , BMI does not seem to influence effects of these regimens on vasomotor symptoms , vaginal atrophy , bleeding profiles , BMD , endometrial safety , or breast pain
HT treatment with estrogens alone or in combination with progestogens was associated with a small to moderate improvement in sexual function , particularly in pain , when used in women with menopausal symptoms or in early postmenopause ( within five years of amenorrhoea ) , but not in unselected postmenopausal women .
The current evidence does not suggest an important effect of tibolone or of SERMs alone or combined with estrogens on sexual function .
BACKGROUND The perimenopausal and postmenopausal periods are associated with many symptoms , including sexual complaints .
OBJECTIVES To assess the effect of hormone therapy ( HT ) on  sexual function in perimenopausal and postmenopausal women .